Immune-mediated lung diseases: A narrative review
The role of immunity in the pathogenesis of various pulmonary diseases, particularly interstitial lung diseases (ILDs), is being increasingly appreciated as mechanistic discoveries advance our knowledge in the field. Immune-mediated lung diseases demonstrate clinical and immunological heterogeneity...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1160755/full |
| _version_ | 1797851395822452736 |
|---|---|
| author | Jaleel Jerry G. Sweis Nabil W. G. Sweis Fatima Alnaimat Jacqueline Jansz Ting-Wei Ernie Liao Ting-Wei Ernie Liao Alaa Alsakaty Abeera Azam Hesham Elmergawy Hali A. Hanson Christian Ascoli Israel Rubinstein Israel Rubinstein Nadera Sweiss |
| author_facet | Jaleel Jerry G. Sweis Nabil W. G. Sweis Fatima Alnaimat Jacqueline Jansz Ting-Wei Ernie Liao Ting-Wei Ernie Liao Alaa Alsakaty Abeera Azam Hesham Elmergawy Hali A. Hanson Christian Ascoli Israel Rubinstein Israel Rubinstein Nadera Sweiss |
| author_sort | Jaleel Jerry G. Sweis |
| collection | DOAJ |
| description | The role of immunity in the pathogenesis of various pulmonary diseases, particularly interstitial lung diseases (ILDs), is being increasingly appreciated as mechanistic discoveries advance our knowledge in the field. Immune-mediated lung diseases demonstrate clinical and immunological heterogeneity and can be etiologically categorized into connective tissue disease (CTD)-associated, exposure-related, idiopathic, and other miscellaneous lung diseases including sarcoidosis, and post-lung transplant ILD. The immunopathogenesis of many of these diseases remains poorly defined and possibly involves either immune dysregulation, abnormal healing, chronic inflammation, or a combination of these, often in a background of genetic susceptibility. The heterogeneity and complex immunopathogenesis of ILDs complicate management, and thus a collaborative treatment team should work toward an individualized approach to address the unique needs of each patient. Current management of immune-mediated lung diseases is challenging; the choice of therapy is etiology-driven and includes corticosteroids, immunomodulatory drugs such as methotrexate, cyclophosphamide and mycophenolate mofetil, rituximab, or other measures such as discontinuation or avoidance of the inciting agent in exposure-related ILDs. Antifibrotic therapy is approved for some of the ILDs (e.g., idiopathic pulmonary fibrosis) and is being investigated for many others and has shown promising preliminary results. A dire need for advances in the management of immune-mediated lung disease persists in the absence of standardized management guidelines. |
| first_indexed | 2024-04-09T19:17:12Z |
| format | Article |
| id | doaj.art-c51e5471a1424283b70b05ad6e70a60e |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-09T19:17:12Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-c51e5471a1424283b70b05ad6e70a60e2023-04-06T05:18:59ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2023-04-011010.3389/fmed.2023.11607551160755Immune-mediated lung diseases: A narrative reviewJaleel Jerry G. Sweis0Nabil W. G. Sweis1Fatima Alnaimat2Jacqueline Jansz3Ting-Wei Ernie Liao4Ting-Wei Ernie Liao5Alaa Alsakaty6Abeera Azam7Hesham Elmergawy8Hali A. Hanson9Christian Ascoli10Israel Rubinstein11Israel Rubinstein12Nadera Sweiss13School of Medicine, The University of Jordan, Amman, JordanSchool of Medicine, The University of Jordan, Amman, JordanDivision of Rheumatology, Department of Internal Medicine, The University of Jordan, Amman, JordanDepartment of Medicine, University of Illinois Chicago, Chicago, IL, United StatesSchool of Medicine, Faculty of Medicine, National Yang Ming Chiao Tung University, Taipei City, TaiwanDivision of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei City, TaiwanDivision of Rheumatology, Department of Medicine, University of Illinois Chicago, Chicago, IL, United StatesDepartment of Internal Medicine, The University of Texas Health Science Center at Tyler, Tyler, TX, United StatesDivision of Rheumatology, Department of Medicine, University of Illinois Chicago, Chicago, IL, United StatesUIC College of Pharmacy, University of Illinois Chicago, Chicago, IL, United StatesDivision of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of Illinois Chicago, Chicago, IL, United StatesDivision of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of Illinois Chicago, Chicago, IL, United States0Research Service, Jesse Brown VA Medical Center, Chicago, IL, United StatesDivision of Rheumatology, Department of Medicine, University of Illinois Chicago, Chicago, IL, United StatesThe role of immunity in the pathogenesis of various pulmonary diseases, particularly interstitial lung diseases (ILDs), is being increasingly appreciated as mechanistic discoveries advance our knowledge in the field. Immune-mediated lung diseases demonstrate clinical and immunological heterogeneity and can be etiologically categorized into connective tissue disease (CTD)-associated, exposure-related, idiopathic, and other miscellaneous lung diseases including sarcoidosis, and post-lung transplant ILD. The immunopathogenesis of many of these diseases remains poorly defined and possibly involves either immune dysregulation, abnormal healing, chronic inflammation, or a combination of these, often in a background of genetic susceptibility. The heterogeneity and complex immunopathogenesis of ILDs complicate management, and thus a collaborative treatment team should work toward an individualized approach to address the unique needs of each patient. Current management of immune-mediated lung diseases is challenging; the choice of therapy is etiology-driven and includes corticosteroids, immunomodulatory drugs such as methotrexate, cyclophosphamide and mycophenolate mofetil, rituximab, or other measures such as discontinuation or avoidance of the inciting agent in exposure-related ILDs. Antifibrotic therapy is approved for some of the ILDs (e.g., idiopathic pulmonary fibrosis) and is being investigated for many others and has shown promising preliminary results. A dire need for advances in the management of immune-mediated lung disease persists in the absence of standardized management guidelines.https://www.frontiersin.org/articles/10.3389/fmed.2023.1160755/fullimmune-mediated lung diseasesinterstitial lung diseaseconnective tissue diseasespost-COVID-19idiopathic pulmonary fibrosissarcoidosis |
| spellingShingle | Jaleel Jerry G. Sweis Nabil W. G. Sweis Fatima Alnaimat Jacqueline Jansz Ting-Wei Ernie Liao Ting-Wei Ernie Liao Alaa Alsakaty Abeera Azam Hesham Elmergawy Hali A. Hanson Christian Ascoli Israel Rubinstein Israel Rubinstein Nadera Sweiss Immune-mediated lung diseases: A narrative review Frontiers in Medicine immune-mediated lung diseases interstitial lung disease connective tissue diseases post-COVID-19 idiopathic pulmonary fibrosis sarcoidosis |
| title | Immune-mediated lung diseases: A narrative review |
| title_full | Immune-mediated lung diseases: A narrative review |
| title_fullStr | Immune-mediated lung diseases: A narrative review |
| title_full_unstemmed | Immune-mediated lung diseases: A narrative review |
| title_short | Immune-mediated lung diseases: A narrative review |
| title_sort | immune mediated lung diseases a narrative review |
| topic | immune-mediated lung diseases interstitial lung disease connective tissue diseases post-COVID-19 idiopathic pulmonary fibrosis sarcoidosis |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2023.1160755/full |
| work_keys_str_mv | AT jaleeljerrygsweis immunemediatedlungdiseasesanarrativereview AT nabilwgsweis immunemediatedlungdiseasesanarrativereview AT fatimaalnaimat immunemediatedlungdiseasesanarrativereview AT jacquelinejansz immunemediatedlungdiseasesanarrativereview AT tingweiernieliao immunemediatedlungdiseasesanarrativereview AT tingweiernieliao immunemediatedlungdiseasesanarrativereview AT alaaalsakaty immunemediatedlungdiseasesanarrativereview AT abeeraazam immunemediatedlungdiseasesanarrativereview AT heshamelmergawy immunemediatedlungdiseasesanarrativereview AT haliahanson immunemediatedlungdiseasesanarrativereview AT christianascoli immunemediatedlungdiseasesanarrativereview AT israelrubinstein immunemediatedlungdiseasesanarrativereview AT israelrubinstein immunemediatedlungdiseasesanarrativereview AT naderasweiss immunemediatedlungdiseasesanarrativereview |